ResMed IncNYSE: RMD

No material news in the last 48 hours.

ResMed announced on May 19, 2026 a partnership with Oura Ring to expand access to sleep health education and care for U.S. members of Oura Ring Gen3 and Ring 4. Separately, longtime CFO Brett Sandercock retired with Aaron Bloomer named successor, and both new CFO and CEO Mick Farrell will present at the William Blair Growth Stock Conference on June 2. The Oura deal extends ResMed's consumer reach into wearables and circadian data. The CFO transition follows a Q3 earnings beat with revenue of $1.43B (+10.8% YoY) and EPS of $2.86, but shares fell 6.7% on the transition news. Risk: leadership change uncertainty plus a recent wearables trial may not yield near-term financial impact.

Resmed and Oura Partnerglobenewswire.comResMed Down 6.7% After Earnings Beatsimplywall.stResMed William Blair Conferenceinvestor.resmed.com

ResMed announced a strategic partnership with Oura on May 19, 2026, to broaden access to sleep health education and care solutions. The collaboration follows Q3 FY26 results showing sales of $1,431.41M and net income of $398.73M, with underlying EBIT up 18% and gross margin expanding 290 bps to 63%. Longtime CFO Brett Sandercock is retiring in May 2026, with former Exact Sciences finance chief Aaron Bloomer succeeding him. Sandercock will remain an advisor through 2027 to ensure continuity. Management will present at the 46th William Blair Growth Stock Conference on June 2. The stock is down 6.7% post-earnings despite the beat, with analysts (Morgan Stanley, Citi, Canaccord, Jarden, Macquarie) maintaining Buy ratings.

ResMed teams up with Oura to enhance sleep health educationgurufocus.comResMed Announces Participation in William Blair Growth Stock Conferenceglobenewswire.comResMed Down 6.7% After Earnings Beat and CFO Transition Newssimplywall.st

ResMed entered a definitive merger agreement in mid-May 2026 to acquire Noctrix Health for $340 million, adding a non-invasive wearable therapy for drug-refractory Restless Legs Syndrome (RLS); the deal is expected to close around June 1, 2026. The fiscal Q3 2026 report (April 30) showed revenue of $1.43B (up 10.8% YoY) and adjusted EPS of $2.86, beating estimates, with mask sales up 12% constant-currency and gross margin expanding 290 bps to 63%. CFO Brett Sandercock's planned May 2026 retirement was reaffirmed, with Aaron Bloomer succeeding him. The board declared a $0.60 quarterly dividend with a May 14 record date. JPMorgan, Morgan Stanley, Citi, and Macquarie maintained Buy ratings in early-mid May, though one analyst issued a Hold citing limited incremental growth from Noctrix. Risk: CFO transition and integration risk on a niche RLS asset amid GLP-1 competitive overhang.

Resmed enters merger agreement to acquire Noctrix Health for $340 millionmassdevice.comResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stResMed Inc stock: dividend in focus after solid Q3 resultsad-hoc-news.de

ResMed shares went ex-dividend on May 14 with a $0.60 quarterly payout (payable June 18). Q3 FY26 results posted earlier delivered 11% revenue growth to $1.43B and EPS of $2.86 beating consensus, with underlying EBIT up 18%, mask sales growth 12% constant-currency, and gross margin expansion of 290bps to 63%. Longtime CFO Brett Sandercock announced retirement with Aaron Bloomer named successor effective May 2026. Despite strong fundamentals and 5.9% cash yield, RMD is down 6.7% after earnings, trading 31% below two-year high. CEO Mick Farrell exercised stock options during NYSE price pressure. Morgan Stanley, Citi, JPM, and Macquarie maintained buy ratings.

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2026investor.resmed.comResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stResMed Ex-dividend date arrives May 14 amid CEO option exercisead-hoc-news.de

ResMed CEO Michael Farrell exercised options for 4,991 shares at $146.34 and sold them at a weighted average $207.82 on May 7, 2026. The board declared a $0.60 per-share quarterly dividend with record date May 14, 2026, payable June 18. Q3 FY26 results posted May 1 showed revenue of $1.43B (+10.8% YoY) and EPS of $2.86 beating estimates, with non-GAAP gross margin expanding 290bp to 63% and underlying EBIT up 18%. The company announced longtime CFO Brett Sandercock's retirement, with Aaron Bloomer named successor. ResMed paid $87M in dividends and repurchased 673,000 shares for $175M. Despite strong fundamentals shares are down ~8.5% over 30 days and ~24% over 90 days, trading near $202. Macquarie, Citi, Morgan Stanley and JPMorgan maintain Buy; Piper Sandler stays Hold.

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026investor.resmed.comResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stResMed CEO exercises options, sells 4,991 sharesstocktitan.net

ResMed entered a definitive agreement to acquire Noctrix Health for $340M, expected to close around June 1, 2026, adding a wearable Restless Legs Syndrome therapy to its portfolio. The board declared a $0.60 quarterly dividend with May 14 record date. Long-time CFO Brett Sandercock retires in May with Aaron Bloomer succeeding him. Q3 FY2026 results showed sales of $1.43B and net income of $398.7M, with underlying EBIT up 18% and gross margin expanding 290bps to 63%. Despite the beat, shares are down ~8.5% over 30 days and ~24% over 90 days, trading at $201.82.

ResMed Acquires Noctrix Health for $340Mmassdevice.comResMed Q3 FY2026 Resultsglobenewswire.comResMed Down After Earnings Beatsimplywall.st

ResMed reported strong Q3 FY26 results with revenue up 11% YoY, 290 bps of gross margin expansion to 63%, and 21% EPS growth, posting $399M net income on $1.43B revenue. Despite the beat, shares declined 6.7% on a 30-day basis on CFO transition concerns, as longtime CFO Brett Sandercock plans May retirement with Aaron Bloomer succeeding. The board declared a $0.60 quarterly dividend payable June 18, record May 14. ResMed announced a new U.S. distribution center in Greenwood, Indiana for 2027 operations. Risk is GLP-1 weight-loss drug overhang on long-term sleep apnea TAM.

ResMed Q3 FY26 Resultsglobenewswire.comResMed Down 6.7% After Beatsimplywall.stResMed Valuation Looksimplywall.st

ResMed reported strong Q3 fiscal 2026 results on April 30, with 11% reported revenue growth to $1,431.41 million, 290 bps of non-GAAP gross margin expansion to 63%, 21% EPS growth, and net income of $399 million (diluted EPS $2.74). Underlying EBIT grew 18% and constant-currency mask sales grew 12%. The Board declared a $0.60 quarterly dividend with record date May 14, payable June 18. The company announced longtime CFO Brett Sandercock's planned May 2026 retirement, with Aaron Bloomer named successor. Analyst Buy ratings were maintained by Citi on May 8, Morgan Stanley on May 7, and J.P. Morgan on May 5, with Piper Sandler holding. Stock trades at $201.82 on May 11.

ResMed Announces Results for Q3 Fiscal Year 2026investor.resmed.comResMed Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stA Look At ResMed Valuation After Strong Earningssimplywall.st

ResMed reported Q3 fiscal 2026 adjusted EPS of $2.86 vs $2.80 estimate on revenue of $1.43 billion (up 11% YoY but missed forecasts). Gross margin expanded 290 bps to 62.8%, operating margin to 36.7%. CFO Brett Sandercock retires in May 2026 with Aaron Bloomer succeeding him. ResMed completed a $340 million Noctrix Health acquisition for restless leg syndrome treatment, expected to reduce Q4 non-GAAP EPS by ~$0.02. Board declared $0.60 quarterly dividend and repurchased 673K shares for $175M. Stock down 8.48% in 30 days and 23.83% over 90 days. Morgan Stanley, Citi, Canaccord maintain Buy.

ResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stResMed Q3 2026 Earnings Call Presentationseekingalpha.comResMed Stock Fell 8% This Weektikr.com

ResMed reported Q3 fiscal 2026 results with 11% revenue growth to $1,431.41 million and 20.7% adjusted EPS increase. CFO Brett Sandercock announced retirement effective May 2026, with Aaron Bloomer appointed successor. The company closed the $340 million Noctrix acquisition for restless leg syndrome treatment. Stock has fallen 22% year-to-date despite strong earnings. Morgan Stanley assigned Buy rating on May 7, 2026, though analysts are reassessing growth assumptions. Consensus analyst rating is Buy with average 12-month price target of $288.56 vs. current $208.

ResMed Inc. (RMD) Latest Stock News & Headlines - Yahoo Financefinance.yahoo.comResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition Newssimplywall.stRMD: Resmed Inc - Stock Price, Quote and News - CNBCcnbc.com

ResMed reported fiscal Q3 2026 net income of $399 million with diluted EPS of $2.74, representing 21% YoY growth. Revenue grew 11% with 290 basis points of gross margin expansion to 63%. However, stock declined 6.7% post-earnings as analysts (Baird, KeyBanc, Citi) lowered price targets citing valuation and growth concerns. CFO Brett Sandercock will retire May 4, 2026, replaced by Aaron Bloomer from Exact Sciences.

ResMed Q3 FY2026 Resultsinvestor.resmed.comResMed Down 6.7% After Earningssimplywall.stResMed Q3 Earnings Callseekingalpha.com

ResMed reported third-quarter fiscal 2026 results (ended March 31, 2026) with 11% revenue growth to $1.4B and 290 basis points of non-GAAP gross margin expansion to 62.2%. Earnings per share increased 21%. The company declared a quarterly dividend of $0.60/share (record date May 14, 2026) and announced Aaron Bloomer as new CFO. ResMed expanded U.S. operations with a new distribution center in Greenwood, Indiana opening in 2027. Product launches include the AirTouch F30i face mask. Global Sleep Survey of 30,000 people across 13 countries released. Analysts maintain Buy rating with 12-month price target of $288.56, representing 38.81% upside.

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026investor.resmed.comResMed Inc. (RMD) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.comNews | Resmed Incnewsroom.resmed.com